Travere Therapeutics, Inc.

Thank you. Thank you. Thank you. Thank you. Thank you. . . . Thank you. Thank you. Thank you.

Good afternoon and welcome to the Tervier Therapeutics fourth quarter and full year 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nera, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.

Thank you, Operator. Good afternoon and welcome to Tervier Therapeutics' fourth quarter and full year 2025 financial results and corporate update call. Thank you all for joining. Today's call will be led by Dr. Eric Dubé, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Dr. Jule Enrich, our Chief Medical Officer, Peter Hirma, our Chief Commercial Officer, and Chris Klein, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A. Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our forms 10Q and 10K filed with the SEC. In addition, any forward-looking statements represent our views only. As of the date such statements are made, February 19, 2026, interviewer specifically disclaims any obligation to update such statements to reflect future information, events, or circumstances. With that, let me now turn the call over to Eric.